Creating an uncommonly strong hemophilia A community with Common Factors

The speakers program for the bleeding disorders community

Common Factors is an innovative CSL Behring program for people with bleeding disorders and their caregivers that gives current insights and information on topics of interest to the bleeding disorders community.

Speakers are doctors, nurses and therapists with unique expertise in bleeding disorders who share their knowledge and shed light on the challenges of living with bleeding disorders. At Common Factors events, patients and caregivers learn more about relevant topics, including:

  • Staying on track with therapy
  • Inhibitors
  • Insurance and reimbursement
  • Pain and anxiety management
  • Aging in hemophilia
  • Hemophlia: A Common Bond

Each event helps patients with bleeding disorders connect with each other and get practical advice. Patients and caregivers form supportive relationships that create a sense of community for all those affected by bleeding disorders.

For more information, contact CSL Behring Consumer Affairs at 1-888-508-6978, or by e-mail at CSL-consumeraffairs@CSLBehring.com.

Next: Healthcare Professional Resources »

Important Safety Information

Helixate® FS, Antihemophilic Factor (Recombinant), is a recombinant factor VIII treatment indicated for the control and prevention of bleeding episodes and peri-operative management in adults and children (0-16 years) with hemophilia A. Helixate® FS is also indicated for routine prophylaxis to reduce the frequency of bleeding episodes and the risk of joint damage in children with hemophilia A with no preexisting joint damage.

The most serious adverse reactions are systemic hypersensitivity reactions and the development of high-titer inhibitors necessitating alternative treatments to antihemophilic factor. The most common adverse reactions observed in clinical trials were inhibitor formation in previously untreated or minimally treated patients, skin-associated hypersensitivity reactions, infusion site reactions, and central venous access device (CVAD) line-associated infections.

Helixate® FS is contraindicated in patients who have manifested life-threatening immediate hypersensitivity reactions, including anaphylaxis, to the product or its components, including mouse or hamster proteins.

Please see the full prescribing information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.